International Journal of Cancer最新文献

{"title":"Hematologic and molecular responses to ropeginterferon alfa-2b therapy of polycythemia vera: 48-week results from a prospective study.","authors":"Seug Yun Yoon, Sung-Soo Yoon, Deok-Hwan Yang, Gyeong-Won Lee, Sang Kyun Sohn, Ho-Jin Shin, Sung Hwa Bae, Chul Won Choi, Eun-Ji Choi, June-Won Cheong, Soo-Mee Bang, Joon Seong Park, Suk Joong Oh, Yong Park, Young Hoon Park, Sung-Eun Lee","doi":"10.1002/ijc.35411","DOIUrl":"https://doi.org/10.1002/ijc.35411","url":null,"abstract":"<p><p>To prevent thrombosis in patients with polycythemia vera (PV), achieving a complete hematologic response (CHR) is highly recommended in practice. In addition, a reduced JAK2 V617F mutation burden is expected to have a disease-modifying effect, and its molecular response (MR) is currently of significant interest. This study aimed to assess the association between CHR and MR in patients with PV following treatment with ropeginterferon alfa-2b. This phase 2, single-arm, open-label, investigator-initiated trial was conducted at 16 sites in South Korea. Ninety-nine patients were treated with ropeginterferon alfa-2b subcutaneously every 2 weeks, at doses of 250 μg (week 1), 350 μg (week 3), and 500 μg (week 5), until week 48. CHRs were 27% (25/94), 46% (40/87), 56% (47/84), and 63% (51/81) at 12, 24, 36, and 48 weeks, respectively. The MR rates were 32% (28/88), 36% (29/81), 49% (38/77), and 57% (42/74) at 12, 24, 36, and 48 weeks, respectively. The Phi Coefficient for the association between CHR and MR was 0.6146 (p < .0001) at 48 weeks. In the subgroup analysis, patients with hydroxyurea resistance or intolerance, and those who were hydroxyurea-naïve, had similar results in terms of the CHR. In conclusion, CHR and MR were observed to be associated in patients with PV treated with ropeginterferon.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143633282","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Temporal trends in incidence and mortality of colorectal cancer in Denmark from 2007 to 2022.","authors":"Ida Ravnsbæk Johannsen, Anders Kindberg Boysen, Frank V Mortensen, Jakob Kirkegård","doi":"10.1002/ijc.35400","DOIUrl":"https://doi.org/10.1002/ijc.35400","url":null,"abstract":"<p><p>Colorectal cancer (CRC) is the third most common cancer in the Western world and represents a significant burden on healthcare systems worldwide. We aimed to describe temporal trends in incidence, tumor characteristics, and survival for patients with CRC in a nationwide, population-based cohort in Denmark. We used population-based Danish healthcare registries to study all patients diagnosed with CRC from 2007 to 2022. Exactly 76,955 people in Denmark were diagnosed with CRC from 2007 to 2022. ASIRs were relatively stable from 2007 to 2013, with an ASIR of 65.8 per 100,000 for colon cancer and 32 per 100,000 for rectal cancer. In 2014, an increase in incidence was observed (79.8 per 100,000 for colon cancer and 37.4 per 100,000 for rectal cancer), followed by a decline in later years. Median survival times were 4.1 (IQR: 0.8 to 14.1) years for patients diagnosed between 2007 and 2010, 5.3 (IQR: 1.1 to -) years for patients diagnosed from 2011 to 2013, and 7.6 (IQR: 1.7 to -) years for patients diagnosed from 2014 to 2017. The assessment of mutational and molecular profiles increased consistently throughout the study period. We observed an initial increase in CRC incidence in 2014, corresponding with the implementation of the national screening program, followed by a subsequent decline. In recent years, the incidence has dropped below pre-screening levels. Additionally, the increasing use of molecular and mutational profiling reflects the growing complexity and multidisciplinary nature of CRC management.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143623038","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of hyperprogressive disease with atezolizumab plus bevacizumab for hepatocellular carcinoma: A secondary analysis of the IMbrave150 trial.","authors":"Yuan Gao, Ann-Lii Cheng, Lee X Li, Natalie Parent, Ganessan Kichenadasse, Christos S Karapetis, Andrew Rowland, Ashley M Hopkins, Michael J Sorich","doi":"10.1002/ijc.35407","DOIUrl":"https://doi.org/10.1002/ijc.35407","url":null,"abstract":"<p><p>The use of Immune checkpoint inhibitors (ICIs) as monotherapy for patients with hepatocellular carcinoma (HCC) has been associated with an increased risk of hyperprogressive disease (HPD), the occurrence of which carries a poor prognosis. However, it is unknown whether contemporary frontline treatment with the combination of atezolizumab and bevacizumab causes significant HPD. This study conducted a secondary analysis of patient-level data from the IMbrave150 randomized controlled trial of atezolizumab plus bevacizumab versus sorafenib for frontline treatment of HCC. Multiple established definitions of early progression and treatment failure applicable to clinical trials were evaluated, including Response Evaluation Criteria in Solid Tumours (RECIST) HPD, HPD based on percent change of sum of longest diameter (SLD HPD), treatment failure HPD (TF HPD), and fast progression (FP). The incidence of these measures was compared between arms. The risk factors for and prognosis of TF HPD were evaluated. The risk of RECIST HPD and TF HPD was significantly lower with atezolizumab plus bevacizumab treatment than with sorafenib treatment-odds ratio for RECIST HPD: 0.29 (95% CI 0.01 to 0.82), TF HPD: 0.30 (0.17, 0.54). TF HPD was similarly associated with poor prognosis, irrespective of treatment arm. High blood alpha-fetoprotein and neutrophil-to-lymphocyte ratio were both associated with an increased risk of TF HPD. For all definitions of early progression/treatment failure, the risk was either significantly lower with atezolizumab plus bevacizumab than with sorafenib, or there were no differences. Atezolizumab plus bevacizumab treatment is unlikely to cause significant HPD.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143623028","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic significance of pre-treatment immune-inflammation biomarkers in anal cancer: A study combining real-world data and a meta-analysis.","authors":"Karen Lycke Wind, Johanne Hollands Steffensen, Anne Vittrup Jakobsen, Camilla Kronborg, Karen-Lise Garm Spindler","doi":"10.1002/ijc.35404","DOIUrl":"https://doi.org/10.1002/ijc.35404","url":null,"abstract":"<p><p>This study examines the prognostic value of pre-treatment inflammatory biomarkers-neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and systemic inflammatory index (SII) in patients with anal cancer (AC). Blood sample analyses from 340 AC patients treated with curative (chemo)radiotherapy were retrieved from patient records to determine pre-treatment NLR, PLR, and SII values. Using receiver operating characteristic curve (RUC) analysis, the Liu method, optimal cut-offs were calculated to 2.96 for NLR, 145.31 for PLR, and 679.86 for SII. Values above the cut-off were significantly associated with worse disease-free survival (DFS) and overall survival (OS). For DFS, the hazard ratios (HRs) were 2.08 for NLR, 1.85 for PLR, and 2.13 for SII, while for OS, the HRs were 1.73 for NLR, 1.14 for PLR, and 1.76 for SII. In multivariate analyses, NLR, PLR, and SII each remained independently significant predictors of DFS. A comprehensive literature review and meta-analysis further substantiated the association between high pre-treatment NLR and OS in AC, although the findings were marked by considerable heterogeneity. These results suggest that NLR, PLR, and SII are valuable and easily measurable prognostic markers in AC. Integrating these biomarkers into clinical practice could enable more personalized treatment strategies by identifying patients at elevated risk of poorer outcomes. Future research should focus on validating these findings across diverse populations and developing standardized methodologies to optimize the clinical utility of these biomarkers.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143623032","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Socioeconomic position and risk of cervical cancer in the Nordic countries: Results from the Nordic Occupational Cancer Study.","authors":"Marzieh Eslahi, Margherita Pizzato, Sanna Heikkinen, Jan Ivar Martinsen, Elsebeth Lynge, Johnni Hansen, Jenny Selander, Ingrid Sivesind Mehlum, Eero Pukkala, Salvatore Vaccarella","doi":"10.1002/ijc.35349","DOIUrl":"https://doi.org/10.1002/ijc.35349","url":null,"abstract":"<p><p>The Nordic countries benefited from declines in cervical cancer incidence rates due to the implementation of screening programmes. However, it is unclear whether all social groups have equally benefited from these preventive services. We provide an assessment of the temporal trends in cervical cancer incidence by socioeconomic position (SEP) in Denmark, Norway, Finland and Sweden, using data from the Nordic Occupational Cancer Study. Truncated age-standardized incidence rates and 95% confidence intervals (CI) of cervical cancer per 100,000 person-years were computed for women aged 50-69 by SEP and country within the period 1961-2005. We used Poisson regression models to compute relative risks (RRs) and 95% CIs of cervical cancer across SEP, pooling data for the three most recent 5-year periods (except for Denmark 1991-1995 and Norway 1991-2003). Throughout the study period, declines in the rates of cervical cancer were observed among all SEP groups. Lower SEP rates, which started from higher values, declined faster than those for higher SEP. At the conclusion of the study period, we still observed a social gradient, with higher rates seen in lower SEP women. Farmers had the lowest risk in all four countries. The RRs for lowest versus highest SEP ranged from 1.33 (95% CI 1.05-1.69) in Sweden to 1.76 (95% CI 1.13-2.85) in Denmark, with a pooled RR of 1.41 (95% CI 1.22-1.64). Lower SEP women still face the highest risks, indicating a need for continued efforts to provide equitable access to preventive services.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143623036","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world treatment patterns and outcomes based on RAS/BRAF status in metastatic colorectal cancer-Analysis of the Prospective Dutch Colorectal Cancer cohort.","authors":"Sietske C M W van Nassau, Koen Zwart, Frederieke H van der Baan, Geraldine R Vink, Marloes A G Elferink, Petur Snaebjornsson, Anne M May, Miriam Koopman, Jeanine M L Roodhart","doi":"10.1002/ijc.35410","DOIUrl":"https://doi.org/10.1002/ijc.35410","url":null,"abstract":"<p><p>The treatment landscape for metastatic colorectal cancer (mCRC) has evolved into a continuum of care with an essential role for biomarkers and molecular subgroups. Treatment guidelines are primarily based on trial results; however, populations and outcomes differ from clinical practice. To support the interpretation of trial results and to assist in tailored patient counseling, we evaluated real-world treatment patterns and outcomes according to RAS/BRAF status. We included all patients diagnosed with BRAF^V600E-mutated mCRC in 2015-2020, participating in the Prospective Dutch Colorectal Cancer cohort study, plus a 1:2 random selection of patients with RAS-mutated and double wild-type mCRC. We evaluated differences in administered lines of treatment (LOTs), local treatment, attrition rates, treatment duration, progression-free survival (PFS) and overall survival (OS). 178 BRAF^V600E-mutated, 221 RAS-mutated, and 174 double wild-type patients were included. Of BRAF^V600E-mutated patients, 26% received ≥3 LOTs, compared to 42% and 47% of the RAS-mutated and double wild-type patients, respectively (p = .002). Local treatment was performed in 25% of BRAF^V600E-mutated, 43% of RAS-mutated, and 49% of double wild-type patients (p < .001). Median OS from diagnosis was 15.4, 24.1, and 32.6 months, respectively (p < .001) and loss of prognostic value of RAS/BRAF was observed from the 3rd LOT onwards (p = .17 and p = .54). This paper provides a comprehensive overview of the treatment landscape of mCRC per RAS/BRAF status in daily clinical practice. The observed substantial treatment heterogeneity within and between molecular subgroups underlines the importance of collecting real-world data to address post-trial knowledge gaps and to optimize individualized counseling for all mCRC patients.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143623034","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Factors associated with diagnostic and treatment intervals in colorectal cancer: A linked data study.","authors":"Allison Drosdowsky, Karen E Lamb, Luc Te Marvelde, Peter Gibbs, Catherine Dunn, Ian Faragher, Ian Jones, Maarten J IJzerman, Jon D Emery","doi":"10.1002/ijc.35414","DOIUrl":"https://doi.org/10.1002/ijc.35414","url":null,"abstract":"<p><p>This research aimed to assess the length of intervals before diagnosis and treatment for colorectal cancer in Australia using linked datasets, and to determine any factors associated with interval length. A colorectal cancer clinical registry was linked to general practice electronic medical record data and routinely collected hospital referral datasets to determine the length of four key intervals in the time before first treatment. Cox proportional hazards regression was used to assess associations between individual characteristics (sociodemographic variables such as age and sex, and disease characteristics such as cancer subtype and treatment approach) and the length of each interval. Sample sizes available for analysis varied by interval, ranging from 99 to 9359. The median interval length ranged from 21 (IQR 5-38) days for the time between diagnosis and treatment to 63 (IQR 24-218) days for the time between first presentation and diagnosis. Overall, few measured characteristics were associated with the lengths of any of the intervals. Of note, shorter diagnostic intervals were associated with presenting to the general practitioner with alarm symptoms, and people proceeding to surgery as initial treatment had shorter times to treatment than any other treatment modality. Given disease and medical system factors were associated with interval length, broad improvements to the overall efficient functioning of the healthcare system are likely to improve timeliness. More targeted interventions could focus on processes at the transitions between different levels of the healthcare system and implementing recommended maximum lengths of intervals along the diagnostic and treatment pathway.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143623030","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The impact of extended invitation intervals on stage distribution of screen-detected and interval cancer within the Dutch colorectal cancer screening program.","authors":"Maria-Alexandra Katsara, Danica van den Berg, Manon C W Spaander, Adriana J van Vuuren, Evelien Dekker, Folkert J van Kemenade, Iris D Nagtegaal, Monique E van Leerdam, Iris Lansdorp-Vogelaar, Esther Toes-Zoutendijk","doi":"10.1002/ijc.35371","DOIUrl":"https://doi.org/10.1002/ijc.35371","url":null,"abstract":"<p><p>This study investigates the impact of extended invitation intervals on the stage distribution of screen-detected and interval colorectal cancers (CRCs) in the Netherlands' fecal immunochemical test (FIT)-based screening program during the COVID-19 pandemic. Using data from individuals with negative FIT results in 2017-2019 and subsequent screening round in 2019-2021, we examined whether delays of up to 6 months affected CRC stage at diagnosis. We performed multivariate logistic regression to assess the association between invitation intervals and cancer stage. Our analysis found no significant difference in stage distribution for both screen-detected and interval CRCs despite the delays. Specifically, odds ratios for late-stage cancer remained close to 1 across various intervals, indicating minimal impact of extended invitation times. These results suggest that the short-term delays caused by the pandemic did not significantly affect the performance of the CRC screening program. This highlights the program's ability to adapt to temporary disruptions while maintaining effective early cancer detection. Our findings support the notion that such disruptions, when managed appropriately, do not substantially compromise the quality of screening outcomes, reinforcing the resilience and flexibility of CRC screening programs in the face of health crises.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143623040","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Latent class analysis-derived classification for cancer-specific death stratification of hepatocellular carcinoma.","authors":"Xiaoyan Jiang, Qianyuan Zhang, Ziying Zheng, Zhiyong Shen, Qiong Luo","doi":"10.1002/ijc.35399","DOIUrl":"https://doi.org/10.1002/ijc.35399","url":null,"abstract":"<p><p>The heterogeneity in prognostic survival and treatment response of hepatocellular carcinoma (HCC) limits the accurate assessment of HCC-specific mortality. This study aimed to identify potential HCC subtypes through latent class analysis (LCA) to improve HCC-specific mortality prediction and optimize treatment recommendations. We analyzed data from 7746 HCC patients in the Surveillance, Epidemiology, and End Results (SEER) databases, incorporating demographic and clinicopathological information and applying LCA to identify HCC subtypes. Prognostic survival and treatment response across different HCC subtypes were evaluated utilizing Cox proportional hazards regression and competing risks models. The classification was externally validated with data from 6791 patients. Four HCC subtypes (LCAC1-LCAC4) were determined. Compared with LCAC1, both LCAC2 (HR = 1.887, p < .001) and LCAC4 (HR = 1.317, p < .001) were associated with significantly shorter overall survival. LCAC2 had the highest HCC-specific mortality (HR: 2.395, p < .001), followed by LCAC4 (HR: 1.531, p < .001), and LCAC3 (HR: 1.424, p < .001). LCAC3 was associated with the lowest risk of non-HCC-specific mortality (HR: 0.613, p < .001). Surgical treatment, particularly preoperative systemic therapy, significantly improved survival across all HCC subtypes, whereas chemotherapy and radiotherapy had limited efficacy in LCAC1 and LCAC3 patients. External validation corroborated these findings. This study provides a classification system that differentiates HCC-specific mortality, facilitating accurate survival stratification and treatment recommendations, and provides valuable insight for clinical decision-making.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143603163","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Antitumor efficacy of intermittent low-dose erlotinib plus sulindac via MHC upregulation and remodeling of the immune cell niche.","authors":"Chakrapani Tripathi, Jorge E Tovar Perez, Sabeeta Kapoor, Ahmed Muhsin, Wan Mohaiza Dashwood, Yunus Demirhan, Melek Demirhan, Alessandro Shapiro, Altaf Mohammed, Shizuko Sei, Jacklyn Thompson, Mahira Zaheer, Krishna M Sinha, Powel H Brown, Michelle I Savage, Eduardo Vilar, Praveen Rajendran, Roderick H Dashwood","doi":"10.1002/ijc.35409","DOIUrl":"10.1002/ijc.35409","url":null,"abstract":"<p><p>A previously reported clinical trial in familial adenomatous polyposis (FAP) patients treated with erlotinib plus sulindac (ERL + SUL) highlighted immune response/interferon-γ signaling as a key pathway. In this study, we combine intermittent low-dose ERL ± SUL treatment in the polyposis in rat colon (Pirc) model with mechanistic studies on tumor-associated immune modulation. At clinically relevant doses, short-term (16 weeks) and long-term (46 weeks) ERL ± SUL administration results in near-complete tumor suppression in Pirc colon and duodenum (p < 0.0001). We identify a low-dose threshold for significant antitumor activity in Pirc rats given SUL at 125 ppm in the diet plus ERL at 5 mg/kg body weight via twice-weekly oral gavage (SUL125 + ERL5 × 2). Longitudinal analyses show diminished expression of MHC class I and II genes in polyps larger than Grade 5, a novel finding in the Pirc model. Treatment with ERL ± SUL upregulates the corresponding MHC and immune-associated factors in a subset of Pirc colon polyps, Pirc tumor cell lines, murine colon carcinoma cells, and FAP patient-derived organoids, with Nlrc5 playing a critical role in this effect. Imaging mass cytometry reveals that SUL125 + ERL5 × 2 increases tumor-associated Cd4⁺ T cells by ~2.6-fold (p < 0.05), with no apparent effect on Cd8⁺ T cells. The treatment also increases tumor-associated Cd68⁺ cells (p < 0.05) and decreases Foxp3⁺ (p < 0.01) and Arg1⁺ (p < 0.05) cells. Thus, intermittent low-dose ERL + SUL treatment enhances tumor-associated MHC expression and remodels the immune cell niche toward a more permissive \"helper\" immune microenvironment. We conclude that early immune-interception strategies targeting interferon-γ signaling may benefit FAP patients at drug doses below the clinical standard of care.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143603156","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}